{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:57:28Z","timestamp":1791205048034,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MH096"],"award-info":[{"award-number":["ZR2023MH096"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Stomatology Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jormas.2026.102829","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:26:59Z","timestamp":1778765219000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in MAPK pathway-targeted therapy for ameloblastoma: A literature review"],"prefix":"10.1016","volume":"127","author":[{"given":"Yitong","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jormas.2026.102829_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/odi.12646","article-title":"Ameloblastoma: current etiopathological concepts and management","volume":"24","author":"Effiom","year":"2018","journal-title":"Oral Dis"},{"key":"10.1016\/j.jormas.2026.102829_bib0002","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00405-015-3631-8","article-title":"Ameloblastoma: a clinical review and trends in management","volume":"273","author":"McClary","year":"2016","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"10.1016\/j.jormas.2026.102829_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23206","article-title":"Efficiency of B-RAF-\/MEK-inhibitors in B-RAF mutated ameloblastoma: case report and review of literature","volume":"9","author":"B\u00fcttner","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jormas.2026.102829_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0975-5950.85849","article-title":"Surgical management of ameloblastoma: conservative or radical approach","volume":"2","author":"Dandriyal","year":"2011","journal-title":"Natl J Maxillofac Surg"},{"key":"10.1016\/j.jormas.2026.102829_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/SAP.0b013e3182a0dedf","article-title":"Aesthetic and functional mandibular reconstruction with immediate dental implants in a free fibular flap and a low-profile reconstruction plate","volume":"74","author":"Shen","year":"2015","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jormas.2026.102829_bib0006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/jop.12807","article-title":"Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: a review","volume":"48","author":"You","year":"2019","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7181\/acfs.2025.0018","article-title":"Molecular-targeted therapy in ameloblastoma: a systematic review","volume":"26","author":"Sulistyani","year":"2025","journal-title":"Arch Craniofac Surg"},{"key":"10.1016\/j.jormas.2026.102829_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/odi.12594","article-title":"TNF\u2010\u03b1\u2010induced IL\u20106 and MMP\u20109 expression in immortalized ameloblastoma cell line established by hTERT","volume":"23","author":"Ohta","year":"2017","journal-title":"Oral Dis"},{"key":"10.1016\/j.jormas.2026.102829_bib0009","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.jormas.2026.102829_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jormas.2026.102829_bib0011","article-title":"ERK\/MAPK signalling pathway and tumorigenesis (review)","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0012","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-14-1069","article-title":"Activating FGFR2\u2013RAS\u2013BRAF mutations in ameloblastoma","volume":"20","author":"Brown","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jormas.2026.102829_bib0013","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1002\/cam4.2931","article-title":"Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma","volume":"9","author":"Kondo","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0014","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1007\/s13277-015-3238-0","article-title":"Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours","volume":"36","author":"Diniz","year":"2015","journal-title":"Tumor Biol"},{"key":"10.1016\/j.jormas.2026.102829_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/jop.13538","article-title":"Molecular pathogenesis of ameloblastoma","volume":"53","author":"Mar\u00edn-M\u00e1rquez","year":"2024","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225593","article-title":"BRAF V600E mutation in ameloblastoma: a systematic review and meta-analysis","volume":"14","author":"Mamat @ Yusof","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jormas.2026.102829_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41368-022-00170-8","article-title":"Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis","volume":"14","author":"Togni","year":"2022","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.jormas.2026.102829_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5306\/wjco.v11.i1.31","article-title":"Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine\/threonine kinase V600E mutation: systematic review","volume":"11","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0019","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41379-018-0194-4","article-title":"KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features","volume":"32","author":"Coura","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jormas.2026.102829_bib0020","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.2986","article-title":"Identification of recurrent SMO and BRAF mutations in ameloblastomas","volume":"46","author":"Sweeney","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jormas.2026.102829_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2021.740788","article-title":"The molecular pathology of odontogenic tumors: expanding the spectrum of MAPK pathway driven tumors","volume":"2","author":"Guimar\u00e3es","year":"2021","journal-title":"Front Oral Health"},{"key":"10.1016\/j.jormas.2026.102829_bib0022","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/ijo.2013.2010","article-title":"Anti-apoptotic role of the sonic hedgehog signaling pathway in the proliferation of ameloblastoma","volume":"43","author":"Kanda","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/path.4317","article-title":"High frequency of BRAF V600E mutations in ameloblastoma","volume":"232","author":"Kurppa","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.jormas.2026.102829_bib0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jop.12024","article-title":"Assessment of protein expression and gene status of human epidermal growth factor receptor (<scp>HER<\/scp>) family molecules in ameloblastomas","volume":"42","author":"Oikawa","year":"2013","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/03008207.2014.923875","article-title":"Matrix metalloproteinase expression in keratocystic odontogenic tumors and primary cells","volume":"55","author":"Amm","year":"2014","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.jormas.2026.102829_bib0026","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0714.2009.00812.x","article-title":"Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model","volume":"39","author":"Zhang","year":"2010","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4802-y","article-title":"Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation","volume":"18","author":"Fernandes","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jormas.2026.102829_bib0028","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.oooo.2015.12.016","article-title":"BRAF inhibitor treatment of primary BRAF -mutant ameloblastoma with pathologic assessment of response","volume":"122","author":"Tan","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jormas.2026.102829_bib0029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/cancers10060157","article-title":"Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAFV600E-specific inhibitor)","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jormas.2026.102829_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122174","article-title":"Anti-MAPK targeted therapy for ameloblastoma: case report with a systematic review","volume":"16","author":"Raemy","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jormas.2026.102829_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01204","article-title":"Enabling precision medicine for rare head and neck tumors: the example of BRAF\/MEK targeting in patients with metastatic ameloblastoma","volume":"9","author":"Brunet","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0032","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.oraloncology.2015.07.010","article-title":"BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology","volume":"51","author":"Brunner","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jormas.2026.102829_bib0034","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/term.3254","article-title":"Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration","volume":"15","author":"Hirschhorn","year":"2021","journal-title":"J Tissue Eng Regen Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jormas.2026.102829_bib0036","first-page":"19","article-title":"Immunoexpression of BRAF, EGFR and CD10 in ameloblastoma","volume":"44","author":"Tan","year":"2022","journal-title":"Malays J Pathol"},{"key":"10.1016\/j.jormas.2026.102829_bib0037","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40496-016-0085-z","article-title":"Molecular signaling in benign odontogenic neoplasia pathogenesis","volume":"3","author":"Amm","year":"2016","journal-title":"Curr Oral Health Rep"},{"key":"10.1016\/j.jormas.2026.102829_bib0039","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-21-0066","article-title":"Differential outcomes in codon 12\/13 and codon 61 NRAS-mutated cancers in the phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors","volume":"27","author":"Cleary","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jormas.2026.102829_bib0040","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/00220345221100773","article-title":"New ameloblastoma cell lines enable preclinical study of targeted therapies","volume":"101","author":"Nguyen","year":"2022","journal-title":"J Dent Res"},{"key":"10.1016\/j.jormas.2026.102829_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106585","article-title":"Treatment options for advanced ameloblastoma in the era of precision medicine: a brief review","volume":"146","author":"Oh","year":"2023","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0042","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0043","article-title":"Precision medicine: sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma","volume":"5","author":"Lawson-Michod","year":"2022","journal-title":"Cancer Rep"},{"key":"10.1016\/j.jormas.2026.102829_bib0044","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.47682","article-title":"The role of BRAF inhibitors in the management of ameloblastoma: a literature review","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jormas.2026.102829_bib0045","first-page":"905","article-title":"METTL1 facilitates ameloblastoma invasive growth via MAPK signaling pathway","author":"Wang","year":"2024","journal-title":"Gene"},{"key":"10.1016\/j.jormas.2026.102829_bib0046","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/jid.2011.313","article-title":"P53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition","volume":"132","author":"Ji","year":"2012","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jormas.2026.102829_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105854","article-title":"Managing stage 4 ameloblastoma with dual BRAF\/MEK inhibition: a case report with 8-year clinical follow-up","volume":"128","author":"Abramson","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jormas.2026.102829_bib0048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41368-024-00281-4","article-title":"Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma","volume":"16","author":"Xiong","year":"2024","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.jormas.2026.102829_bib0049","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1002\/cam4.2667","article-title":"Hypoxia-induced HIF-1\u03b1 and ZEB1 are critical for the malignant transformation of ameloblastoma via TGF-\u03b2-dependent EMT","volume":"8","author":"Yoshimoto","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12105-024-01734-2","article-title":"Histopathologic and molecular insights following the management of ameloblastomas via targeted therapies \u2013 pathological and clinical perspectives","volume":"18","author":"Hirschhorn","year":"2024","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.jormas.2026.102829_bib0051","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1111\/odi.14962","article-title":"Targeted therapies in ameloblastomas and amelobastic carcinoma\u2014a systematic review","volume":"30","author":"Bologna-Molina","year":"2024","journal-title":"Oral Dis"},{"key":"10.1016\/j.jormas.2026.102829_bib0052","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jop.13494","article-title":"Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta-analysis and metaregression","volume":"52","author":"Singh","year":"2023","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0053","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00223-023-01177-x","article-title":"Resolution of PTHrP-mediated hypercalcemia following treatment with dual BRAF\/MEK inhibition for BRAFV600E-positive metastatic ameloblastoma","volume":"114","author":"Corbett","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jormas.2026.102829_bib0054","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jormas.2026.102829_bib0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41368-025-00364-w","article-title":"Programmed death-ligand 1 regulates ameloblastoma growth and recurrence","volume":"17","author":"Zhang","year":"2025","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.jormas.2026.102829_bib0056","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jormas.2026.102829_bib0057","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic Braf induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jormas.2026.102829_bib64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","article-title":"Oncogenic Braf induces melanocyte senescence and melanoma in mice","volume":"15","author":"Dhomen","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Journal of Stomatology Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468785526001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468785526001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:45:53Z","timestamp":1791204353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468785526001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2468785526001254"],"URL":"https:\/\/doi.org\/10.1016\/j.jormas.2026.102829","relation":{},"ISSN":["2468-7855"],"issn-type":[{"value":"2468-7855","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in MAPK pathway-targeted therapy for ameloblastoma: A literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Stomatology Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jormas.2026.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}